COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations

Marco Morrone; Matteo Scotto Di Vetta; Serafino Fazio

文献导航

搜索文章

搜索思路

钛学术文献服务平台 \
学术期刊 \
综合期刊 \
其它期刊 \
世界荟萃分析杂志期刊 \
COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations

COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations

作者：

Marco Morrone Matteo Scotto Di Vetta Serafino Fazio

基本信息来源于合作网站，原文需代理用户跳转至来源网站获取

COVID-19

Evidence

based

medicine

Hydroxycloroquine

Azithromycine

Indomethacine

DOXYCYCLINE

摘要：

The world pandemic due to coronavirus disease 2019,known as COVID-19,embodies a high rate of disease transmission that causes a critical hospitalization overload.As of May 15,2020,the disease has been the cause of more than 4 million infections and more than 280000 deaths all over the world.At the beginning,we underestimated the disease;now,we have sufficient information and it is clear that it is not just a respiratory disease.In fact,if a prompt treatment is not initiated,the disease may evolve towards an abnormal immune response and cytokine storm with an important thrombophilic pattern.Therefore,we think that while waiting for certainties to be established by evidence-based medicine,it is not ethical to not try off-label therapies for some of the well-known drugs,as they could have some efficacy based on their mechanisms of action.

内容分析

关键词云

关键词热度

相关文献总数

(/次)

(/年)

文献信息

篇名	COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations
来源期刊	世界荟萃分析杂志	学科	医学
关键词	COVID-19 Evidence based medicine Hydroxycloroquine Azithromycine Indomethacine DOXYCYCLINE
年，卷（期）	2020,（3）	所属期刊栏目
研究方向		页码范围	173-177
页数	5页	分类号	R95
字数		语种
DOI